In a similar study involving patients with end-stage renal disease (ESRD), who were undergoing dialysis, medical costs were found to be 8.9% higher for every month of treatment when Serum Hb was less than 11 gm/dL [2]. This evidence concerns the gene GSTM1 and chronic kidney disease.